Exforge Generic Deal Is Clear Antitrust Violation, Court Told
By Matthew Perlman ( October 25, 2018, 5:25 PM EDT) -- A proposed class of drug buyers told a New York federal court Wednesday that an agreement between Novartis Pharmaceuticals Corp. and Par Pharmaceutical Inc. that allegedly delayed the launch of a generic version of hypertension medication Exforge is illegal on its face and doesn't need a closer look....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.